Video and article in this news post courtesy of NewsChannel 9, Syracuse NY, Kendra Broddus.
Associated Medical Professionals of NY is pleased to announce that it has treated the first patient in the U.S. with a new pre-chemotherapy treatment. On March 28, the Food and Drug Administration approved Pluvicto, a new radiation agent able to treat patients with prostate cancer pre-chemotherapy. The A.M.P. patient is under the care of Steven E. Finkelstein, M.D., DABR, FACRO, Director of the Center of Advanced Radiation Excellence (CARE) and Director Radiation Oncology Research.
Christopher M. Pieczonka, M.D., CEO of A.M.P., stated, “We are so excited to be able to add Pluvicto to the armamentarium for treating our metastatic castrate resistant prostate patients. For many of these patients who have failed first-line therapy, chemotherapy is a daunting option. The availability of using radiopharmaceutical treatment instead of the standard options allows patients to have significant delay in progression of their cancer with very acceptable side effects.”
Steven Finkelstein, M.D., DABR, FACRO, Director of the Center of Advanced Radiation Excellence (CARE) and Director Radiation Oncology Research of A.M.P., stated, “Pluvicto is a first of its kind, what’s called theragnostic. Theragnostics are treatments where you can image the cancer and see exactly where it is, using an advanced imaging modality called PET-CT scans. Then there’s a targeted agent, which in this case is a radiation agent, which can go and attack those sites of disease and treat exactly where that spot of cancer is.”
Dr. Finkelstein was also interviewed by UroToday regarding this groundbreaking treatment.
Read article here.
Learn more about Radiation Oncology at Associated Medical Professionals (A.M.P.)
